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Misidentifications of Burkholderia pseudomallei as Burkholderia cepacia by Vitek 2 have occurred. Multidimensional scaling
ordination of biochemical profiles of 217 Malaysian and Australian B. pseudomallei isolates found clustering of misidentified B.
pseudomallei isolates from Malaysian Borneo. Specificity of B. pseudomallei identification in Vitek 2 and potentially other auto-
mated identification systems is regionally dependent.
Burkholderia pseudomallei is a saprophytic soil bacterium thatcauses melioidosis, a disease endemic in northern Australia
and Southeast Asia affecting humans and animals (1). The clinical
presentations of melioidosis range from skin infections without
sepsis to disseminated infection with sepsis and high mortality.
Pneumonia is present in around half of cases, and chronic infec-
tions, relapsed disease, and activation from latency are all recog-
nized (1, 2).
Confirmation of diagnosis of melioidosis requires a positive
culture of B. pseudomallei from clinical samples such as blood,
sputum, urine, pus, joint aspirate, or swabs from throat or rectum
(1). B. pseudomallei has been identified by combining the com-
mercial API 20NE biochemical kit (bioMérieux) with a simple
screening system involving Gram stain, oxidase reaction, typical
growth characteristics, and resistance to gentamicin (3). Suscep-
tibility to amoxicillin-clavulanate (AMC) has also been used to
differentiate B. pseudomallei from Burkholderia cepacia, which is
resistant to AMC (4). Unfamiliarity with B. pseudomallei and
problems with inaccurate species identification using some auto-
mated commercial biochemical identification systems have re-
sulted in laboratories misidentifying the bacterium as a Pseudomo-
nas or other Burkholderia species (5–9). Confirmation of B.
pseudomallei identity by real-time PCR of DNA extracted from
cultured bacterial colonies is increasingly the standard for many
laboratories (10). Various genetic targets have been published for
PCR identification of B. pseudomallei from bacterial cultures and
also for direct detection from clinical samples, with a recent review
showing the type III secretion system (TTS1)-orf2 assay to be su-
perior in detecting B. pseudomallei directly from clinical speci-
mens (11). Apart from molecular methods, B. pseudomallei from
cultures can also be confirmed by antigen detection assays, such as
latex agglutination (12). More recently, matrix-assisted laser de-
sorption ionization–time of flight mass spectrometry (MALDI-
TOF MS) has been adapted to identify cultured bacteria based on
protein fingerprint profiles (13).
A particular problem has been the misidentification of B. pseu-
domallei as Burkholderia cepacia by the Vitek 2 automated bio-
chemical system (bioMérieux) (5–8). B. cepacia belongs to a group
of 17 phenotypically and genotypically similar species which form
the B. cepacia complex, with B. cepacia specifically noted as an
opportunistic pathogen infecting and causing progressive pulmo-
nary deterioration in patients with cystic fibrosis (14, 15). Other
organisms that have been reportedly misidentified by the Vitek 2
system include Candida albicans being misidentified as Gram-
negative bacilli (16) and Candida parapsilosis being misidentified
as Candida famata (17).
We have compared the Vitek 2 system biochemical profiles of
68 confirmed B. pseudomallei clinical strains from hospitals in
Sabah and Sarawak, Malaysian Borneo, with 149 B. pseudomallei
and 18 B. cepacia isolates from the Royal Darwin Hospital (RDH)
in Northern Territory, Australia. One isolate per patient was ana-
lyzed. All isolates were collected between September 2010 and
June 2012, except for 17 isolates collected in 1994 from Sabah.
All isolates were subcultured on horse blood agar (HBA) be-
fore testing was performed on the Vitek 2 according to the man-
ufacturer’s instructions (bioMérieux). The Vitek 2 system utilizes
a panel of biochemical and enzymatic tests which results in a bio-
chemical profile that is compared against the manufacturer’s bac-
terial taxa database. All B. pseudomallei isolates were confirmed by
both real-time PCR targeting the well-validated B. pseudomallei
TTS1 (10) and by a latex agglutination test (12). Of the isolates
from Sarawak, 15/43 (35%) had been initially identified as B. ce-
pacia by the Vitek 2 system but were subsequently confirmed as B.
pseudomallei by both the TTS1 real-time PCR and the latex agglu-
tination test (Table 1). These 15 patients were from hospitals from
different regions in Sarawak, none had cystic fibrosis, and me-
lioidosis was suspected clinically, with a diversity of clinical pre-
sentations, including subcutaneous infection, community-ac-
quired pneumonia, and sepsis. Only 2/25 B. pseudomallei isolates
from Sabah and 3/149 B. pseudomallei isolates from Darwin were
misidentified as B. cepacia (Table 1).
Using Primer version 6 (Primer-E Ltd., Plymouth Marine Lab-
oratory, United Kingdom), we performed a nonmetric multidi-
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